Pathways’ Picks July 14: De Novo Rule, Doc Pay, Guidance Picks, and More

article image

In this week’s roundup: A look ahead to FDA’s upcoming final rule on the de novo classification program; Medicare’s proposed Physician Fee Schedule contends with AI, physician-owned distributorships, and colon cancer screening; guidance documents from Europe, China, the US, and Canada; a new MDR notified body and more.

An FDA de novo final rule is coming soon, while CMS’ Physician Fee Schedule proposed rule is out this week. We look at both of those and a lot more in the latest edition of Pathways’ Picks.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: